BJMO - volume 12, issue 4, august 2018
M. Rasschaert MD, L. Triest MD, J. Van den Brande , K. Papadimitriou MD, H. Prenen MD, PhD, M. Peeters MD, PhD
The 2018 annual meeting of the American Society of Oncology (ASCO) was once more hosted in Chicago. Over 40,000 oncologists attended this years’ convention. This report will summarize the highlights from the gastro-intestinal cancer sessions at the meeting.
Read moreBJMO - volume 11, issue 7, november 2017
L. Triest MD, K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
ESMO 2017 featured the presentation of several practice changing data in the field of gastrointestinal (GI) cancer. The first part of this report will summarize the key data presented in the field of gastric cancer, gastroesophageal junction (GEJ), biliary, gallbladder, biliary, pancreatic and hepatocellular cancer. In the second part, the focus is turned to colorectal cancer.
(BELG J ONCOL 2017;11(7):340–348)
Read moreBJMO - volume 11, issue 4, september 2017
K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
The 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) took place once more in Chicago from June 2 to 6, bringing together more than 30,000 oncology professionals from around the world. This year’s meeting theme is “Making a Difference in Cancer Care with You.” Studies spanning the spectrum of GI cancer prevention and care, from new standards of care to immunotherapy and precision medicine, will be highlighted.
Read moreBJMO - volume 10, issue 5, august 2016
K. Papadimitriou MD, T. Van den Mooter MD, J. Van den Brande , M. Rasschaert MD, M. Peeters MD, PhD
During the 2016 ASCO Annual Meeting, a robust body of phase III trials was presented in the gastrointestinal (GI) oncology field, including updates and interesting post-hoc analyses. Once more, the early phase research was mainly focused on immunotherapy, with some promising results.
(BELG J MED ONCOL 2016;10(5):150–155)
Read moreBJMO - volume 9, issue 6, november 2015
K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
A large body of trials, including large adjuvant phase III trials up to early phase trials was presented during the 2015 European Cancer Congress (ECC). Immunotherapy, was once more in the center of the scientific interest for different types of cancer and settings. This report will focus on some of the key studies presented during the meeting, referring to gastrointestinal cancer.
(BELG J MED ONCOL 2015;9:217–21)
Read moreBJMO - volume 9, issue 4, august 2015
K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
The 2015 ASCO Annual Meeting represents the 50th anniversary celebration from ASCO’s foundation. This is the beginning of the second half of our first 100 years. We’re going to think about what cancer and cancer care delivery will look like 10, 20, or 30 years from now,” said the 2014– 2015 ASCO President, Peter Paul Yu. The chosen theme of this year’s meeting is “Illumination and Innovation: Transforming Data into Learning” as reflected in Dr. Yu’s question “How do we harness our vastly increasing knowledge base and deliver the fruits of that labor to our patients?”
In gastrointestinal oncology results, updates and sub analyses of phase III trials were presented but also many negative trials. Data from early phase trials in the fields of immunology, incorporating new promising treatments like anti-PD-1, potential related markers and HER2 receptor blockage were also of interest. Furthermore, debates with a focus on financial aspects of treatment approaches, including the innovative, but yet very expensive immune modulation therapies, and comparisons of standard “targeted” approaches were discussed.
(BELG J MED ONCOL 2015;9:143–8)
Read more
Top
